FindTrial
Sign In

Clinical study on the difference of MR features and prognoses between hepatocellular carcinoma (HCC) and combined hepatocellular cholangiocarcinoma (cHCC-CCA) with CCA component less than 10%

Clinical study on the difference of MR features and prognoses between hepatocellular carcinoma (HCC) and combined hepatocellular cholangiocarcinoma (cHCC-CCA) with CCA component less than 10%

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058428
Enrollment
Unknown
Registered
2022-04-09
Start date
2022-06-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Combined hepatocellular cholangiocarcinoma

Interventions

None listed

Sponsors

Zhongshan Hospital, Fudan University, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with combined hepatocellular-cholangiocarcinoma by pathological examination, and the proportion of CCA component is less than 10%; 2. Patients with hepatocellular carcinoma confirmed by pathological examination.

Exclusion criteria

Exclusion criteria: 1. Patients who have received anti-tumor treatment; 2. Patients who are allergic to magnetic resonance contrast agents; 3. The claustrophobic patients.

Design outcomes

Primary

MeasureTime frame
Recurrence;Adverse Events;—

Secondary

MeasureTime frame
Death;—

Countries

China

Contacts

Public ContactChun Yang

Zhongshan Hospital, Fudan University

yang.chun1@zs-hospital.sh.cn+86 18702135336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026